Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10

Abstract

We previously reported Frizzled homolog 10 (FZD10), a member of the Frizzled family, to be a promising therapeutic target for synovial sarcomas. In this report, we established a murine monoclonal antibody (MAb), namely, MAb 92-13 that had specific binding activity against native

Critical Roles of Mucin 1 Glycosylation by Transactivated PolypeptideN-Acetylgalactosaminyltransferase 6 in Mammary Carcinogenesis

“…(3,4). We have identified several cancer-specific molecules and characterized them for possible application to development of cancer therapy (5,6,20,38,39). In the present study, we characterized a novel breast cancer-specific molecule, GALNT6, encoding an O-glycosyltransferase and showed its potential as a druggable target by showing its critical roles in the growth of breast cancer cells.…”

“…To generate anti-GALNT6 polyclonal antibodies, partial recombinant GALNT6 protein (codons 35-179) was purified and inoculated into rabbits, as described previously (9). In addition, because of the limited amount of above polyclonal antibody, we also generated mouse anti-GALNT6 monoclonal antibodies, as described previously (20). The hybridomas were subcloned to assess the ability to recognize GALNT6 protein.…”

Cell-Permeable Peptide DEPDC1-ZNF224 Interferes with Transcriptional Repression and Oncogenicity in Bladder Cancer Cells

“…Therefore, we have established our effective screening system to identify therapeutic targets as well as biological function analysis of their functionally relevant partners toward development of agents that have specific and efficient anticancer effects with lower risk of adverse reactions. Through the gene expression profile analysis of various kinds of cancer, we have identified several cancer-specific molecules and characterized them for possible application to development of cancer therapy (8,(22)(23)(24)(25). Among them, we here report characterization of DEPDC1 as a druggable target by showing its critical roles in bladder carcinogenesis.…”

International Union of Basic and Clinical Pharmacology. LXXX. The Class Frizzled Receptors

“…A WNT-2 antibody was able to induce apoptosis in malignant melanoma cells and to reduce tumor growth (You et al, 2004). Monoclonal antibodies MAb 92-13 raised against FZD 10 and coupled to yttrium-90 were capable to reduce tumor growth of synovial sarcoma in a Xenograft mouse model suggesting its use for radioimmunotherapy even in patients (Fukukawa et al, 2008). Antibody strategies were used not only in cancer models but were also extended to rheumatoid arthritis, where anti-FZD 5 antibodies reduced IL-6 and IL-15 expression in fibroblast-like synoviocytes (Sen et al, 2001).…”